Food allergy, biologics and the economics of sustainable practice growth
Clinical innovation is expanding what allergy and immunology practices can offer. The business opportunity is substantial, but its value will depend on how effectively a practice converts appropriate care into reliable collections, usable capacity and durable patient relationships.
New treatment options can raise gross revenue while also increasing drug purchasing exposure, authorization work and follow-up demands. At the same time, longer dosing intervals and home administration can change the role of the treatment room. A five-year plan built only around visit volume or drug revenue can therefore miss the most important economic changes.
This brief examines the evidence behind those shifts and translates it into a practical operating agenda for physician owners, administrators and healthcare executives. Its central proposition: the next phase of growth should be measured by contribution margin and patient access together.
CDC data show that 31.7% of U.S. adults and 29.5% of children had at least one of three diagnosed conditions in 2024: seasonal allergy, eczema or food allergy. These categories overlap and should not be added together. For an independent practice, population prevalence is the beginning of the opportunity assessment — the commercially relevant questions are local…
Free. The download unlocks right here the moment you subscribe — no waiting on an email. One subscription unlocks every ORYNT brief.
We never ask for patient data. Unsubscribe any time. Privacy
Put the outlook to work on your own numbers.
SEE THE PLANNER